Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0RUQKB
ADC Name	WO2015189791A1 ADC-30
Synonyms	WO2015189791A1_ADC-30 Click to Show/Hide
Organization	GEIERSTANGER.Bernhard
Drug Status	Investigative
Indication	In total 1 Indication(s) Breast cancer [ICD11:2C60-2C65] Investigative
Drug-to-Antibody Ratio	2
	3D MOL	2D MOL
Antibody Name	Anti-HER2 antibody 20507		Antibody Info
Antigen Name	Receptor tyrosine-protein kinase erbB-2 (ERBB2)		Antigen Info
Payload Name	Undisclosed
Linker Name	WO2015189791A1 ADC-30 linker

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 4 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	0.06	nM	CVCL_1259	Breast ductal carcinoma
Half Maximal Inhibitory Concentration (IC50)	0.09	nM	CVCL_1603	Gastric tubular adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	0.16	nM	CVCL_2077	Breast ductal carcinoma
Half Maximal Inhibitory Concentration (IC50)	> 41	nM	CVCL_0132	Amelanotic melanoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 4 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.06 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	HCC1954 cells		CVCL_1259
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.09 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.16 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Breast ductal carcinoma	JIMT-1 cells		CVCL_2077
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 41.00 nM	Moderate HER2 expression (HER2++)
Method Description	Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

References

Ref 1	Auristatin derivatives and conjugates thereof.